Cancers (Mar 2022)

Deep Learning Facilitates Distinguishing Histologic Subtypes of Pulmonary Neuroendocrine Tumors on Digital Whole-Slide Images

  • Marius Ilié,
  • Jonathan Benzaquen,
  • Paul Tourniaire,
  • Simon Heeke,
  • Nicholas Ayache,
  • Hervé Delingette,
  • Elodie Long-Mira,
  • Sandra Lassalle,
  • Marame Hamila,
  • Julien Fayada,
  • Josiane Otto,
  • Charlotte Cohen,
  • Abel Gomez-Caro,
  • Jean-Philippe Berthet,
  • Charles-Hugo Marquette,
  • Véronique Hofman,
  • Christophe Bontoux,
  • Paul Hofman

DOI
https://doi.org/10.3390/cancers14071740
Journal volume & issue
Vol. 14, no. 7
p. 1740

Abstract

Read online

The histological distinction of lung neuroendocrine carcinoma, including small cell lung carcinoma (SCLC), large cell neuroendocrine carcinoma (LCNEC) and atypical carcinoid (AC), can be challenging in some cases, while bearing prognostic and therapeutic significance. To assist pathologists with the differentiation of histologic subtyping, we applied a deep learning classifier equipped with a convolutional neural network (CNN) to recognize lung neuroendocrine neoplasms. Slides of primary lung SCLC, LCNEC and AC were obtained from the Laboratory of Clinical and Experimental Pathology (University Hospital Nice, France). Three thoracic pathologists blindly established gold standard diagnoses. The HALO-AI module (Indica Labs, UK) trained with 18,752 image tiles extracted from 60 slides (SCLC = 20, LCNEC = 20, AC = 20 cases) was then tested on 90 slides (SCLC = 26, LCNEC = 22, AC = 13 and combined SCLC with LCNEC = 4 cases; NSCLC = 25 cases) by F1-score and accuracy. A HALO-AI correct area distribution (AD) cutoff of 50% or more was required to credit the CNN with the correct diagnosis. The tumor maps were false colored and displayed side by side to original hematoxylin and eosin slides with superimposed pathologist annotations. The trained HALO-AI yielded a mean F1-score of 0.99 (95% CI, 0.939–0.999) on the testing set. Our CNN model, providing further larger validation, has the potential to work side by side with the pathologist to accurately differentiate between the different lung neuroendocrine carcinoma in challenging cases.

Keywords